Abstracts Archive - Page 897 of 2607 - ACR Meeting Abstracts

Abstract Number: 0909 • ACR Convergence 2020
Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study
Iain McInnes¹, Philip Mease², Dafna Gladman³, Laura Coates⁴, Peter Nash⁵, Alexis Ogdie⁶, Frank Behrens⁷, Philippe Goupille⁸, Arthur Kavanaugh⁹, Ruvie Martin¹⁰, Erhard Quebe-Fehling¹¹ and Corine Gaillez¹¹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Oxford, Oxford, United Kingdom, ⁵School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁶University of Pennsylvania, Philadelphia, PA, ⁷CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁸CHU Tours, department of rheumatology, Tours, France, ⁹Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…
Abstract Number: 0910 • ACR Convergence 2020
Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2
Philip Mease¹, Laura Coates², Filip Van den Bosch³, Philip Helliwell⁴, Dafna Gladman⁵, Leen Gilles⁶, Lien Gheyle⁶, Mona Trivedi⁷, Muhsen Alani⁸ and Robin Besuyen⁹, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²University of Oxford, Oxford, United Kingdom, ³Ghent University Hospital, Ghent, Belgium, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁶Galapagos NV, Mechelen, Belgium, ⁷Gilead Sciences, Inc., Foster City, CA, ⁸Gilead Sciences, Inc. and University of Washington, Foster City, CA, ⁹Galapagos BV, Leiden, Netherlands
Background/Purpose: EQUATOR (NCT03101670) was a 16-week, Phase 2, double-blind, randomized placebo-controlled trial of filgotinib for PsA. At Week 16, placebo-treated patients could switch to filgotinib…
Abstract Number: 0911 • ACR Convergence 2020
Impact of Filgotinib on Structural Lesions in the Sacroiliac Joints at 12 Weeks in Patients with Active Ankylosing Spondylitis: Correlation with Clinical Endpoints
Walter Maksymowych¹, Mikkel Østergaard², Robert Landewé³, William Barchuk⁴, Ke Liu⁴, Chantal Tasset⁵, Leen Gilles⁵, Thijs Hendrikx⁶, Robin Besuyen⁶ and Xenofon Baraliakos⁷, ¹University of Alberta, Edmonton, AB, Canada, ²Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ³Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Galapagos BV, Leiden, Netherlands, ⁷Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany
Background/Purpose: In the Phase 2 TORTUGA trial (NCT03117270), the oral, selective Janus kinase 1 inhibitor filgotinib reduced inflammation in patients with active ankylosing spondylitis (AS),…
Abstract Number: 0912 • ACR Convergence 2020
Effectiveness of DETECT Algorithm in Japanese Systemic Sclerosis Patients with Old or New Hemodynamic Definition of Pulmonary Arterial Hypertension
Takanori Ito¹, Takehiro Nakai², Genki Kidoguchi², Sho Fukui², Hiroki Ozawa², Satoshi Kawaai², Yukihiko Ikeda², Hisanori Shimizu², Yasuhiro Suyama³, Atsushi Nomura², Hiromichi Tamaki¹, Kenichi Yamaguchi² and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ³JR Tokyo General Hospital, Tokyo, Japan
Background/Purpose: Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) has been known as a life-threatening manifestation in SSc. Earlier detection and subsequent interventions are important to improve…
Abstract Number: 0913 • ACR Convergence 2020
Systemic Sclerosis Portends a Higher Risk of Conduction and Rhythm Disorders at Diagnosis and During Disease Course: Results from a US Population Based Study
Yasser Radwan¹, Reto Kurmann², Avneek Singh Sandhu³, Edward El-Am⁴, Cynthia Crowson², Eric Matteson⁵, Thomas Osborn², Kenneth Warrington⁶, Rekha Mankad² and Ashima Makol², ¹Mayo Clinic, Rochester, Minnesota, USA, Lansing, MI, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic, Rochester, Minnesota, USA, Dayton, OH, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, MN, ⁶Mayo Clinic, Rochester, MN
Background/Purpose: Cardiac involvement, including electrocardiogram (ECG) abnormalities, is associated with worse prognosis in systemic sclerosis (SSc). We studied the incidence, risk factors and outcomes of…
Abstract Number: 0914 • ACR Convergence 2020
Serious Infections in People with Systemic Sclerosis: A National U.S. Study
Jasvinder Singh¹ and John Cleveland¹, ¹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To study incidence, time-trends and outcomes of serious infections in systemic sclerosis (SSc).Methods: We used the 1998-2016 U.S. National Inpatient Sample data. We examined…
Abstract Number: 0915 • ACR Convergence 2020
Clinical Bedside Tools to Assess Systemic Sclerosis Vasculopathy: Can Digital Thermal Monitoring and Sublingual Microscopy Identify Patients with Current or past Digital Ulcers?
Tracy Frech¹, Zhining Ou², Julie Thomas² and Angela Presson², ¹University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT
Background/Purpose: Sublingual microscopy is reported as a useful tool for vasculopathy assessment in SSc. Digital thermal monitoring (DTM) correlates with flow-mediated dilatation, and may identify…
Abstract Number: 0916 • ACR Convergence 2020
Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis
Fiza Ahmed¹, Svetlana Nihtyanova¹, Stamatia Chatzinikolaou², Voon Ong¹, Charles Murray² and Christopher Denton³, ¹Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ²Department of Gastroenterology, Royal Free London Foundation Trust, UK, London, United Kingdom, ³University College London, London, United Kingdom
Background/Purpose: Patients with systemic sclerosis (SSc) frequently experience gastrointestinal (GI) symptoms, ranging from mild to debilitating in severity. Better prediction of those most at risk…
Abstract Number: 0917 • ACR Convergence 2020
Drug-Drug Interaction Study of Nintedanib (Ofev®) and the Combination of Ethinylestradiol and Levonorgestrel (Microgynon®) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Madelon Vonk¹, Mandy Avis², Kristell Marzin³, Salome Mack³, Sven Wind³ and Martina Gahlemann⁴, ¹Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands, ²Boehringer Ingelheim B.V., Alkmaar, The Netherlands, Alkmaar, Netherlands, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, Germany, ⁴Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Nintedanib is a tyrosine kinase inhibitor that has been approved for the treatment of SSc-ILD. As nintedanib may cause fetal harm, patients taking nintedanib…
Abstract Number: 0918 • ACR Convergence 2020
Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and Without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial
Kristin Highland¹, Gerard Criner², Petros Sfikakis³, Hilario Nunes⁴, Wendy Stevens⁵, Corinna Miede⁶, Margarida Alves⁷ and Michael Kreuter⁸, ¹Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ²Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ³National Kapodistrian University of Athens Medical School, Athens, Greece, ⁴Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France, Bobigny, France, ⁵Department of Rheumatology, St Vincent's Hospital, Melbourne, Victoria, Australia, Fitzroy, Victoria, Australia, ⁶mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany, Heidelberg, Germany
Background/Purpose: Gastroesophageal reflux disease (GERD) is a common comorbidity in patients with SSc-ILD and may be associated with progression of SSc-ILD. In the SENSCIS trial…
Abstract Number: 0919 • ACR Convergence 2020
Determinants of Health-related Quality of Life in Systemic Sclerosis
Nina van Leeuwen¹, Jacopo Ciaffi², Sophie Liem², Thomas Huizinga² and Jeska de Vries-Bouwstra², ¹LUMC, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Systemic Sclerosis (SSc) is a heterogeneous disease, in which multiple manifestations are associated with considerable morbidity and mortality. Cross sectional studies have shown that…
Abstract Number: 0920 • ACR Convergence 2020
Machine Learning Assisted Prediction of Progression in Systemic Sclerosis Patients: An Approach to Concise, Tailored Model Construction Using Outpatient Clinical Data
Nina van Leeuwen¹, Marc Maurits², Sophie Liem², Jacopo Ciaffi², Nina Ajmone Marsan², Maarten Ninaber², Thomas Huizinga² and Jeska de Vries-Bouwstra², ¹LUMC, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Systemic Sclerosis (SSc) disease course can range from mild, to very severe with progressive organ involvement within months. Guidelines for follow-up are mainly based…
Abstract Number: 0921 • ACR Convergence 2020
The Hospital Anxiety and Depression Scale in Patients with Systemic Sclerosis – A Psychometric and Factor Analysis in a Monocentric Cohort
Alexandru Garaiman¹, Carina Mihai¹, Rucsandra Dobrota¹, Suzana Jordan¹, Britta Maurer², Jan Flemming³, Oliver Distler⁴ and Mike Oliver Becker¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, ³Department of Consultation-Liaison-Psychiatry and Psychosomatic Medicine, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: The Hospital Anxiety and Depression Scale (HADS) is a screening tool used in patients with different medical conditions. However, its validity, reliability and responsiveness…
Abstract Number: 0922 • ACR Convergence 2020
Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex
Christopher Mecoli¹, Brittany Adler², Qingyuan Yang², Laura Hummers³, Antony Rosen², Livia Casciola-Rosen⁴ and Ami Shah⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Univerisity, Ellicott City, MD, ⁴Johns Hopkins University, Johns Hopkins University, MD, ⁵Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: The aim of this study is to describe four of the most common autoantibodies against components of the Th/To complex: hPOP1, RPP25, RPP30, and…
Abstract Number: 0923 • ACR Convergence 2020
Criteria for the Diagnosis of Raynaud’s Phenomenon – Do They Recognize the Same Patients?
Martina Plešivčnik-Novljan¹, Daša Šuput Skvarča¹, Ajda Jezernik¹, Saša Čučnik¹, Žiga Rotar¹ and Alojzija Hocevar², ¹University Medical Center Ljubljana, Ljubljana, Ljubljana, Slovenia, ²University Medical Center, Rheumatology, Ljubljana, LJUBLJANA, Slovenia
Background/Purpose: Different criteria aiding the diagnosis of Raynaud’s phenomenon (RP) have been proposed. Wigley’s “RP criteria 2002”, defined RP by history of cold sensitivity, accompanied…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].